Packaging and tiers best practices for 2026 for healthcare and life sciences in Southern Europe
The current, revised best practices for packaging and tiers — updated for what actually works in the buyer environment of 2026. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Southern Europe.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Southern Europe. In this market, Southern European buyers reward relationship depth over transactional outreach, so the way you install packaging and tiers has to be shaped to that reality from day one.
Best practices for packaging and tiers have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.
Best practice one: fewer accounts, sharper triggers. The wrong tier structure caps deal size for years, and generic coverage is now negative signal.
Best practice two: publish average contract value by tier weekly. If leadership does not see the number, the model quietly drifts.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Southern Europe it is compounded by the fact that relationship depth, not activity volume is what actually gates growth. Packaging and tiers is only useful here when it is pointed at both constraints at once.
Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.
Best practice four: name a single owner. Committees produce compromise; owners produce numbers.
Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.
Best practice six: run monthly retrospectives that are honest about what did not work. Packaging and tiers improves faster on failure data than on success data.
Concretely for healthcare and life sciences in Southern Europe: the healthcare teams that install this get past procurement instead of dying in it, and a single trusted Southern European relationship compounds into a regional beachhead. That is the reason it is worth installing packaging and tiers deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Pricing · healthcare · Southern Europe — answered
- Does packaging and tiers work for healthcare and life sciences in Southern Europe?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Southern Europe, Southern European buyers reward relationship depth over transactional outreach. The healthcare teams that install this get past procurement instead of dying in it.
- What changed in packaging and tiers best practices for 2026?
- Buyers are less tolerant of generic coverage; specificity and trigger quality now dominate.
- Which best practice is most under-implemented?
- Pre-written kill criteria. Almost no team has them; every team benefits from them.
- Do best practices change by company size?
- Governance scales with size; core principles remain identical.
- How do I know a best practice is working?
- Average contract value by tier improves, and improvements survive a month.
- What is the Southern Europe-specific pitfall when running packaging and tiers for healthcare?
- Importing a playbook that was built for another market. In Southern Europe, Southern European buyers reward relationship depth over transactional outreach — the install has to reflect that.
Growth Broker editorial
Filed under pricing · healthcare · southern europe